Riskpilot← Back to searchSign inGet full accessQuantBioRes A/S
A/SActiveCVR 41407352Gyngemose Parkvej 3, 3. tvManufacture of pharmaceutical preparations · NACE 2120Est. 2020— employees
Revenue 2024
DKK -820K
-49% vs 2023
EBITDA margin
100.0%
+49% vs 2023
Equity ratio
-1000.4%
Financial strength
Net profit 2024
DKK -1,5M
-10% vs 2023
| Revenue | DKK -820K | -49% |
| EBITDA | DKK -820K | +49% |
| Net profit | DKK -1,5M | -10% |
| Total assets | DKK 883K | -25% |
| Equity | DKK -8,8M | -20% |
| Employees | — | — |
Legal name
QuantBioRes A/S
CVR number
41407352
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
3. juni 2020
Share capital
DKK 700.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af 2 bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed indenfor medico, handel og anden dermed i forbindelse stående virksomhed.
Address
Gyngemose Parkvej 3, 3. tv
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -1.347 | -2.907 | -3.770 | -1.621 | -820 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -1.361 | -2.907 | -3.770 | -1.621 | -820 |
| Depreciation & amort. | -5 | -17 | -17 | -17 | -70 |
| EBIT | -1.366 | -2.924 | -3.787 | -1.638 | -890 |
| Net financials | -0 | -14 | -3 | -16 | -4 |
| Profit before tax | -1.366 | -2.938 | -3.791 | -1.653 | -895 |
| Tax | -266 | -592 | -726 | -311 | 587 |
| Net profit | -1.101 | -2.345 | -3.065 | -1.342 | -1.482 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 837 | 1.081 | 964 | 1.185 | 883 |
| Equity | -601 | -2.946 | -6.011 | -7.353 | -8.835 |
| Long-term debt | 1.359 | 3.992 | 6.739 | 8.420 | 9.673 |
| Short-term debt | 78 | 35 | 236 | 119 | 45 |
| Total debt | 1.437 | 4.027 | 6.975 | 8.538 | 9.718 |
EBITDA margin
-82013000.0%
This company
15.8%
Market median
-519069720% vs market
20202024
Equity ratio
-1000.4%
This company
38.2%
Market median
-2719% vs market
20202024
Return on equity
-148206500.0%
This company
18.4%
Market median
-805470209% vs market
20202024
Net profit margin
-148206500.0%
This company
8.1%
Market median
-1829709977% vs market
20202024
Asset turnover
-0.93×
This company
1.12×
Market median
-183% vs market
20202024
Debt / equity
1.10×
This company
0.62×
Market median
-77% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-06-03 – 2020-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
IL Management | Management | 2020 | — | — |
TD | Founder | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 66.7% | 66.7% | 2025 | |
| Individual | 10.0% | 10.0% | 2025 | |
| Individual | 10.0% | 10.0% | 2025 | |
| Individual | 10.0% | 10.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of QuantBioRes A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ivan Loncarevic | Management | 0 companies |
| TULUA DOO BEOGRAD - STARI GRAD | Founder | 0 companies |
| Christian Isak Charles Dahlager | Board of Directors | 0 companies |
| Anthony Slingsby | Board of Directors | 0 companies |
| Novak Djokovic | Board of Directors | 0 companies |
| Mark Andrew Madden | Board of Directors | 0 companies |